New pill aims to slow lung scarring in IPF patients

NCT ID NCT06764862

Completed Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested an experimental tablet called HSK44459 in 186 adults with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. Participants took one of three doses of the drug or a placebo twice daily for 12 weeks. The main goal was to see if the drug could improve or preserve lung function, measured by forced vital capacity (FVC).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HSK44459
What this could lead to: If successful, this could point toward a new oral treatment to slow lung function decline in people with idiopathic pulmonary fibrosis.
What could go wrong: This is a mid-stage trial with only 186 participants over 12 weeks, so results may not confirm long-term benefit or safety. The drug may not improve lung function more than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.